Benchmark reports bumper revenues
Benchmark Holdings, which develops vaccines to keep fish healthy rather than using antibiotics to treat disease, has reported significant growth in revenues and underlying profit ahead of market expectations.
The Sheffield-based firm reported a 7 per cent increase in revenue to £150m for the year to the end of September. EBITDA rose 65 per cent to £16.5m.
The group said market conditions in its core salmon and shrimp markets remain favourable and the outlook is positive, with strong demographic and sustainability drivers.